We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




BioMérieux’s New Automated Tests for Chikungunya Virus Diagnosis Offer Better Traceability

By LabMedica International staff writers
Posted on 16 May 2022

Chikungunya virus (CHIKV) is transmitted to humans by certain mosquitoes. More...

Due to the significant spread of these mosquitoes throughout the world, this infection which was originally present in only tropical regions, has now been described and can be acquired locally in many countries, including recently in temperate climates like North America and Europe. Now, new tests for the diagnosis of CHIKV infection aim to help improve access to medically important automated diagnostic tests in low- and middle-income countries.

bioMérieux (Marcy-l'Étoile, France) has launched the new CE-Marked VIDAS Anti-CHIKUNGUNYA IgM and Anti-CHIKUNGUNYA IgG automated tests intended as an aid in the diagnosis of CHIKV infection. These serological assays, as recommended by international guidelines, can detect Chikungunya infection during the acute phase and into the chronic phase. Their development has been based on methods and technologies from the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID).

Used on the VIDAS family platforms, the VIDAS Anti- CHIKUNGUNYA IgM and IgG tests provide reliable results with better traceability than existing manual methods. Their performance and accuracy allow the differentiation of this diagnosis from other similar febrile syndromes caused by infections such as dengue or malaria. Based on single-sample testing and “Load & Go” concepts, the VIDAS Anti- CHIKUNGUNYA IgM and IgG are easy to use and accessible to all laboratories. Relying on bioMérieux’s expertise in infectious diseases, these serological assays enable clear-cut results with no equivocal zone and an objective interpretation.

“This new VIDAS CHIKUNGUNYA panel complements the VIDAS DENGUE solution launched last year,” said Pierre Boulud, Chief Operating Officer, Clinical Operations, bioMérieux. “Our offer of immunoassays directed against vector-borne diseases helps improve access to medically important automated diagnostic tests in low- and middle-income countries. The large VIDAS installed base in these countries allows fast and wide availability of these tests.”

Related Links:
bioMérieux


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.